The Food and Drug Administration presented the preliminary results of a study on the asthma drug Singulair, which is sold generically as montelukast, to a "limited audience" at the American College of Toxicology meeting in Austin, Texas on Nov. 20, according to Reuters, which reviewed the scientific presentation.

Lab tests showed "significant binding" of the drug to multiple brain receptors, according to Jessica Oliphant, a deputy director at FDA's National Center for Toxicological Research. However, research does not show whether the binding leads to the harmful side effects from the drug.

Looks like they need to do some more research on the side effects of this popular asthma medication.